CA2345377A1 - Nouvelles proteines secretees, et polynucleotides les codant - Google Patents

Nouvelles proteines secretees, et polynucleotides les codant Download PDF

Info

Publication number: CA2345377A1
Authority: CA; Canada
Prior art keywords: mamm; nucleic acid; seq; protein; polypeptide
Prior art date: 1998-10-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002345377A

Other languages

English (en)

Inventor

Richard A. Shimkets

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

CuraGen Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-06

Filing date

1999-10-06

Publication date

2000-04-13

1999-10-06 Application filed by CuraGen Corp filed Critical CuraGen Corp

2000-04-13 Publication of CA2345377A1 publication Critical patent/CA2345377A1/fr

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title abstract description 528
102000004169 proteins and genes Human genes 0.000 title abstract description 410
102000040430 polynucleotide Human genes 0.000 title abstract description 18
108091033319 polynucleotide Proteins 0.000 title abstract description 18
239000002157 polynucleotide Substances 0.000 title abstract description 18
238000000034 method Methods 0.000 claims abstract description 176
230000000694 effects Effects 0.000 claims abstract description 156
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 142
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 105
229920001184 polypeptide Polymers 0.000 claims abstract description 95
239000012634 fragment Substances 0.000 claims abstract description 67
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 66
230000027455 binding Effects 0.000 claims abstract description 24
238000001514 detection method Methods 0.000 claims abstract description 22
230000001575 pathological effect Effects 0.000 claims abstract description 10
150000007523 nucleic acids Chemical class 0.000 claims description 242
210000004027 cell Anatomy 0.000 claims description 233
102000039446 nucleic acids Human genes 0.000 claims description 224
108020004707 nucleic acids Proteins 0.000 claims description 224
125000003729 nucleotide group Chemical group 0.000 claims description 114
239000002773 nucleotide Substances 0.000 claims description 111
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 100
241000282414 Homo sapiens Species 0.000 claims description 94
239000000523 sample Substances 0.000 claims description 84
239000013598 vector Substances 0.000 claims description 57
201000010099 disease Diseases 0.000 claims description 47
230000000295 complement effect Effects 0.000 claims description 33
150000001413 amino acids Chemical class 0.000 claims description 32
239000012472 biological sample Substances 0.000 claims description 27
241000124008 Mammalia Species 0.000 claims description 25
230000015572 biosynthetic process Effects 0.000 claims description 22
238000004519 manufacturing process Methods 0.000 claims description 18
238000006243 chemical reaction Methods 0.000 claims description 11
230000007423 decrease Effects 0.000 claims description 9
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 8
239000002853 nucleic acid probe Substances 0.000 claims description 8
108010010469 Qa-SNARE Proteins Proteins 0.000 claims description 6
102000050389 Syntaxin Human genes 0.000 claims description 6
238000012258 culturing Methods 0.000 claims description 4
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
108010005730 R-SNARE Proteins Proteins 0.000 claims description 2
102000002215 Synaptobrevin Human genes 0.000 claims description 2
108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 claims description 2
229910001424 calcium ion Inorganic materials 0.000 claims description 2
102100030552 Synaptosomal-associated protein 25 Human genes 0.000 claims 2
102000004129 N-Type Calcium Channels Human genes 0.000 claims 1
108090000699 N-Type Calcium Channels Proteins 0.000 claims 1
230000006052 T cell proliferation Effects 0.000 claims 1
108040000979 soluble NSF attachment protein activity proteins Proteins 0.000 claims 1
235000018102 proteins Nutrition 0.000 abstract description 398
238000011282 treatment Methods 0.000 abstract description 47
239000000126 substance Substances 0.000 abstract description 18
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 3
235000018417 cysteine Nutrition 0.000 abstract description 3
108010000499 Thromboplastin Proteins 0.000 abstract description 2
102000002262 Thromboplastin Human genes 0.000 abstract description 2
230000002357 endometrial effect Effects 0.000 abstract description 2
150000003431 steroids Chemical class 0.000 abstract description 2
101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 abstract 1
102000046353 human CXCL2 Human genes 0.000 abstract 1
230000014509 gene expression Effects 0.000 description 114
108020004414 DNA Proteins 0.000 description 107
150000001875 compounds Chemical class 0.000 description 81
238000003556 assay Methods 0.000 description 77
239000003795 chemical substances by application Substances 0.000 description 74
239000003814 drug Substances 0.000 description 57
210000001519 tissue Anatomy 0.000 description 57
208000035475 disorder Diseases 0.000 description 53
108020004999 messenger RNA Proteins 0.000 description 50
239000013615 primer Substances 0.000 description 50
241001465754 Metazoa Species 0.000 description 48
238000012360 testing method Methods 0.000 description 46
206010028980 Neoplasm Diseases 0.000 description 45
239000013604 expression vector Substances 0.000 description 45
230000000692 anti-sense effect Effects 0.000 description 43
239000000203 mixture Substances 0.000 description 42
230000035772 mutation Effects 0.000 description 40
238000003752 polymerase chain reaction Methods 0.000 description 38
238000009396 hybridization Methods 0.000 description 37
235000001014 amino acid Nutrition 0.000 description 35
239000002299 complementary DNA Substances 0.000 description 34
230000001225 therapeutic effect Effects 0.000 description 34
102000037865 fusion proteins Human genes 0.000 description 33
108020001507 fusion proteins Proteins 0.000 description 33
108091028043 Nucleic acid sequence Proteins 0.000 description 31
210000001744 T-lymphocyte Anatomy 0.000 description 30
229940024606 amino acid Drugs 0.000 description 30
230000001105 regulatory effect Effects 0.000 description 28
229940079593 drug Drugs 0.000 description 27
239000003446 ligand Substances 0.000 description 26
239000000427 antigen Substances 0.000 description 24
108091007433 antigens Proteins 0.000 description 24
102000036639 antigens Human genes 0.000 description 24
108091034117 Oligonucleotide Proteins 0.000 description 23
230000006870 function Effects 0.000 description 23
108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
201000011510 cancer Diseases 0.000 description 22
230000002401 inhibitory effect Effects 0.000 description 20
238000003199 nucleic acid amplification method Methods 0.000 description 20
230000009261 transgenic effect Effects 0.000 description 20
102000004190 Enzymes Human genes 0.000 description 19
108090000790 Enzymes Proteins 0.000 description 19
125000000539 amino acid group Chemical group 0.000 description 19
230000003321 amplification Effects 0.000 description 19
210000000349 chromosome Anatomy 0.000 description 19
229940088598 enzyme Drugs 0.000 description 19
239000012528 membrane Substances 0.000 description 19
210000004379 membrane Anatomy 0.000 description 19
108010076504 Protein Sorting Signals Proteins 0.000 description 18
230000001594 aberrant effect Effects 0.000 description 18
239000000463 material Substances 0.000 description 18
-1 2155647 Chemical class 0.000 description 17
108700019146 Transgenes Proteins 0.000 description 17
238000007423 screening assay Methods 0.000 description 17
230000000875 corresponding effect Effects 0.000 description 16
238000002360 preparation method Methods 0.000 description 16
108091026890 Coding region Proteins 0.000 description 15
230000001413 cellular effect Effects 0.000 description 15
238000003776 cleavage reaction Methods 0.000 description 15
238000000338 in vitro Methods 0.000 description 15
102000005962 receptors Human genes 0.000 description 15
108020003175 receptors Proteins 0.000 description 15
230000004663 cell proliferation Effects 0.000 description 14
239000003153 chemical reaction reagent Substances 0.000 description 14
239000000047 product Substances 0.000 description 14
230000000069 prophylactic effect Effects 0.000 description 14
230000007017 scission Effects 0.000 description 14
210000002435 tendon Anatomy 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
241000699666 Mus <mouse, genus> Species 0.000 description 13
238000010171 animal model Methods 0.000 description 13
230000012010 growth Effects 0.000 description 13
210000000056 organ Anatomy 0.000 description 13
230000035755 proliferation Effects 0.000 description 13
230000004071 biological effect Effects 0.000 description 12
230000004927 fusion Effects 0.000 description 12
238000001727 in vivo Methods 0.000 description 12
230000003993 interaction Effects 0.000 description 12
208000015122 neurodegenerative disease Diseases 0.000 description 12
230000002974 pharmacogenomic effect Effects 0.000 description 12
238000003259 recombinant expression Methods 0.000 description 12
238000002054 transplantation Methods 0.000 description 12
102000053602 DNA Human genes 0.000 description 11
239000000556 agonist Substances 0.000 description 11
210000003917 human chromosome Anatomy 0.000 description 11
230000028993 immune response Effects 0.000 description 11
230000004044 response Effects 0.000 description 11
238000006467 substitution reaction Methods 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
201000001320 Atherosclerosis Diseases 0.000 description 10
108090000994 Catalytic RNA Proteins 0.000 description 10
102000053642 Catalytic RNA Human genes 0.000 description 10
241000238631 Hexapoda Species 0.000 description 10
230000004075 alteration Effects 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
230000000903 blocking effect Effects 0.000 description 10
230000002068 genetic effect Effects 0.000 description 10
238000002744 homologous recombination Methods 0.000 description 10
230000006801 homologous recombination Effects 0.000 description 10
230000001939 inductive effect Effects 0.000 description 10
210000003734 kidney Anatomy 0.000 description 10
230000036210 malignancy Effects 0.000 description 10
238000013507 mapping Methods 0.000 description 10
239000003550 marker Substances 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
108091092562 ribozyme Proteins 0.000 description 10
238000012216 screening Methods 0.000 description 10
230000004936 stimulating effect Effects 0.000 description 10
102100026445 A-kinase anchor protein 17A Human genes 0.000 description 9
101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 description 9
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
239000005557 antagonist Substances 0.000 description 9
239000012707 chemical precursor Substances 0.000 description 9
210000003041 ligament Anatomy 0.000 description 9
238000001890 transfection Methods 0.000 description 9
210000004881 tumor cell Anatomy 0.000 description 9
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
108091033380 Coding strand Proteins 0.000 description 8
210000003719 b-lymphocyte Anatomy 0.000 description 8
230000024245 cell differentiation Effects 0.000 description 8
230000002759 chromosomal effect Effects 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
230000004069 differentiation Effects 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
230000008569 process Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
208000023275 Autoimmune disease Diseases 0.000 description 7
241000588724 Escherichia coli Species 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
108700026244 Open Reading Frames Proteins 0.000 description 7
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
101710168213 Syncollin Proteins 0.000 description 7
102100026185 Syncollin Human genes 0.000 description 7
230000003399 chemotactic effect Effects 0.000 description 7
230000007547 defect Effects 0.000 description 7
230000007812 deficiency Effects 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
230000002255 enzymatic effect Effects 0.000 description 7
238000001415 gene therapy Methods 0.000 description 7
230000006698 induction Effects 0.000 description 7
210000004962 mammalian cell Anatomy 0.000 description 7
230000004770 neurodegeneration Effects 0.000 description 7
102000054765 polymorphisms of proteins Human genes 0.000 description 7
230000001737 promoting effect Effects 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
150000003384 small molecules Chemical class 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
108010004250 Inhibins Proteins 0.000 description 6
102000002746 Inhibins Human genes 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
108091023040 Transcription factor Proteins 0.000 description 6
102000040945 Transcription factor Human genes 0.000 description 6
241000700605 Viruses Species 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000004913 activation Effects 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 6
239000000872 buffer Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
208000037765 diseases and disorders Diseases 0.000 description 6
210000001671 embryonic stem cell Anatomy 0.000 description 6
210000002472 endoplasmic reticulum Anatomy 0.000 description 6
239000000499 gel Substances 0.000 description 6
210000003958 hematopoietic stem cell Anatomy 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
239000000893 inhibin Substances 0.000 description 6
208000014674 injury Diseases 0.000 description 6
230000003902 lesion Effects 0.000 description 6
230000000670 limiting effect Effects 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
238000012544 monitoring process Methods 0.000 description 6
238000002703 mutagenesis Methods 0.000 description 6
231100000350 mutagenesis Toxicity 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
239000002243 precursor Substances 0.000 description 6
239000002987 primer (paints) Substances 0.000 description 6
238000011321 prophylaxis Methods 0.000 description 6
238000000746 purification Methods 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
239000002904 solvent Substances 0.000 description 6
241000894007 species Species 0.000 description 6
230000008733 trauma Effects 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
108020005544 Antisense RNA Proteins 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
102000002029 Claudin Human genes 0.000 description 5
108050009302 Claudin Proteins 0.000 description 5
206010058314 Dysplasia Diseases 0.000 description 5
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
102000005720 Glutathione transferase Human genes 0.000 description 5
108010070675 Glutathione transferase Proteins 0.000 description 5
208000009329 Graft vs Host Disease Diseases 0.000 description 5
241000282412 Homo Species 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
102000043131 MHC class II family Human genes 0.000 description 5
108091054438 MHC class II family Proteins 0.000 description 5
102000018697 Membrane Proteins Human genes 0.000 description 5
108010052285 Membrane Proteins Proteins 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
108010091086 Recombinases Proteins 0.000 description 5
102000018120 Recombinases Human genes 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
206010052428 Wound Diseases 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
230000009471 action Effects 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
239000011324 bead Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
210000000170 cell membrane Anatomy 0.000 description 5
239000003184 complementary RNA Substances 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
210000003527 eukaryotic cell Anatomy 0.000 description 5
230000001747 exhibiting effect Effects 0.000 description 5
229940028334 follicle stimulating hormone Drugs 0.000 description 5
239000011521 glass Substances 0.000 description 5
208000024908 graft versus host disease Diseases 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
210000004754 hybrid cell Anatomy 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
230000003463 hyperproliferative effect Effects 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
210000000287 oocyte Anatomy 0.000 description 5
210000003463 organelle Anatomy 0.000 description 5
230000002265 prevention Effects 0.000 description 5
230000004952 protein activity Effects 0.000 description 5
230000001603 reducing effect Effects 0.000 description 5
238000011069 regeneration method Methods 0.000 description 5
230000008439 repair process Effects 0.000 description 5
230000010076 replication Effects 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
230000001131 transforming effect Effects 0.000 description 5
238000013519 translation Methods 0.000 description 5
238000001262 western blot Methods 0.000 description 5
108700028369 Alleles Proteins 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 4
239000003155 DNA primer Substances 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 4
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 4
102000043129 MHC class I family Human genes 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
206010054949 Metaplasia Diseases 0.000 description 4
101710163270 Nuclease Proteins 0.000 description 4
108091008109 Pseudogenes Proteins 0.000 description 4
102000057361 Pseudogenes Human genes 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
238000012300 Sequence Analysis Methods 0.000 description 4
108010090804 Streptavidin Proteins 0.000 description 4
238000007792 addition Methods 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
239000000074 antisense oligonucleotide Substances 0.000 description 4
238000012230 antisense oligonucleotides Methods 0.000 description 4
230000006907 apoptotic process Effects 0.000 description 4
238000013459 approach Methods 0.000 description 4
238000003491 array Methods 0.000 description 4
229960002685 biotin Drugs 0.000 description 4
235000020958 biotin Nutrition 0.000 description 4
239000011616 biotin Substances 0.000 description 4
210000000845 cartilage Anatomy 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
230000001659 chemokinetic effect Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
230000001351 cycling effect Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
230000035558 fertility Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
230000005714 functional activity Effects 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
230000011132 hemopoiesis Effects 0.000 description 4
230000002439 hemostatic effect Effects 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
238000000099 in vitro assay Methods 0.000 description 4
238000005462 in vivo assay Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000002372 labelling Methods 0.000 description 4
239000002502 liposome Substances 0.000 description 4
230000033001 locomotion Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
210000001161 mammalian embryo Anatomy 0.000 description 4
230000015689 metaplastic ossification Effects 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000000816 peptidomimetic Substances 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
210000001236 prokaryotic cell Anatomy 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000008093 supporting effect Effects 0.000 description 4
230000008685 targeting Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000017423 tissue regeneration Effects 0.000 description 4
230000005945 translocation Effects 0.000 description 4
230000000472 traumatic effect Effects 0.000 description 4
230000004614 tumor growth Effects 0.000 description 4
241000701447 unidentified baculovirus Species 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
108010059616 Activins Proteins 0.000 description 3
102000005606 Activins Human genes 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
241000972773 Aulopiformes Species 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010006187 Breast cancer Diseases 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
108020004635 Complementary DNA Proteins 0.000 description 3
102100021704 Cytochrome P450 2D6 Human genes 0.000 description 3
230000004568 DNA-binding Effects 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
206010062016 Immunosuppression Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
108091092724 Noncoding DNA Proteins 0.000 description 3
238000000636 Northern blotting Methods 0.000 description 3
239000004365 Protease Substances 0.000 description 3
108020004518 RNA Probes Proteins 0.000 description 3
239000003391 RNA probe Substances 0.000 description 3
241000700159 Rattus Species 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
108010083644 Ribonucleases Proteins 0.000 description 3
102000006382 Ribonucleases Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000000488 activin Substances 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
108091008324 binding proteins Proteins 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000003200 chromosome mapping Methods 0.000 description 3
239000013068 control sample Substances 0.000 description 3
230000004940 costimulation Effects 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
239000002612 dispersion medium Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000001476 gene delivery Methods 0.000 description 3
230000003394 haemopoietic effect Effects 0.000 description 3
230000035876 healing Effects 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000007901 in situ hybridization Methods 0.000 description 3
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
230000021633 leukocyte mediated immunity Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
230000009826 neoplastic cell growth Effects 0.000 description 3
210000000944 nerve tissue Anatomy 0.000 description 3
230000007170 pathology Effects 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
208000033808 peripheral neuropathy Diseases 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
230000004043 responsiveness Effects 0.000 description 3
238000012552 review Methods 0.000 description 3
235000019515 salmon Nutrition 0.000 description 3
230000037390 scarring Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000001082 somatic cell Anatomy 0.000 description 3
239000000758 substrate Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
210000001550 testis Anatomy 0.000 description 3
230000002537 thrombolytic effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000032258 transport Effects 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
101710112984 20 kDa protein Proteins 0.000 description 2
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
208000032467 Aplastic anaemia Diseases 0.000 description 2
208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
241000557626 Corvus corax Species 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
239000003298 DNA probe Substances 0.000 description 2
108091029865 Exogenous DNA Proteins 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
241000233866 Fungi Species 0.000 description 2
208000000321 Gardner Syndrome Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010071602 Genetic polymorphism Diseases 0.000 description 2
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
108091027305 Heteroduplex Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
101710159910 Movement protein Proteins 0.000 description 2
208000031888 Mycoses Diseases 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
241001494479 Pecora Species 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
208000006994 Precancerous Conditions Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
108010065868 RNA polymerase SP6 Proteins 0.000 description 2
101000643626 Rattus norvegicus Syncollin Proteins 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
208000006011 Stroke Diseases 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
101710090398 Viral interleukin-10 homolog Proteins 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000002730 additional effect Effects 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
230000011748 cell maturation Effects 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
230000035605 chemotaxis Effects 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
208000029664 classic familial adenomatous polyposis Diseases 0.000 description 2
238000000576 coating method Methods 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
238000002742 combinatorial mutagenesis Methods 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
238000002316 cosmetic surgery Methods 0.000 description 2
230000000139 costimulatory effect Effects 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
238000004163 cytometry Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
239000003599 detergent Substances 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
230000028023 exocytosis Effects 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000003176 fibrotic effect Effects 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
210000000497 foam cell Anatomy 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
102000055297 human CXCL1 Human genes 0.000 description 2
230000000260 hypercholesteremic effect Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
230000008611 intercellular interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
230000031864 metaphase Effects 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
210000002500 microbody Anatomy 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
239000011707 mineral Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
230000033607 mismatch repair Effects 0.000 description 2
238000000329 molecular dynamics simulation Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
210000000066 myeloid cell Anatomy 0.000 description 2
210000003061 neural cell Anatomy 0.000 description 2
201000001119 neuropathy Diseases 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000002674 ointment Substances 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
208000027232 peripheral nervous system disease Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000007505 plaque formation Effects 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
235000019419 proteases Nutrition 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000012857 radioactive material Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
210000001578 tight junction Anatomy 0.000 description 2
230000009772 tissue formation Effects 0.000 description 2
230000008467 tissue growth Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
108010087967 type I signal peptidase Proteins 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
230000003827 upregulation Effects 0.000 description 2
239000004474 valine Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NLEBIOOXCVAHBD-YHBSTRCHSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-YHBSTRCHSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
206010001557 Albinism Diseases 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108020005224 Arylamine N-acetyltransferase Proteins 0.000 description 1
102100038110 Arylamine N-acetyltransferase 2 Human genes 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003594 Ataxia telangiectasia Diseases 0.000 description 1
208000034172 Autoimmune Experimental Myasthenia Gravis Diseases 0.000 description 1
208000030767 Autoimmune encephalitis Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
101001057129 Bacillus cereus Enterotoxin Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
208000005692 Bloom Syndrome Diseases 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
101001069913 Bos taurus Growth-regulated protein homolog beta Proteins 0.000 description 1
241001598984 Bromius obscurus Species 0.000 description 1
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
102000001902 CC Chemokines Human genes 0.000 description 1
108010040471 CC Chemokines Proteins 0.000 description 1
YLQWXOJZHJBROT-UHFFFAOYSA-O CONC[S+]=C(NC=C1)NC1=O Chemical compound CONC[S+]=C(NC=C1)NC1=O YLQWXOJZHJBROT-UHFFFAOYSA-O 0.000 description 1
108050006947 CXC Chemokine Proteins 0.000 description 1
102000019388 CXC chemokine Human genes 0.000 description 1
101150010738 CYP2D6 gene Proteins 0.000 description 1
240000001432 Calendula officinalis Species 0.000 description 1
235000005881 Calendula officinalis Nutrition 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000001843 Carotid Body Tumor Diseases 0.000 description 1
208000037211 Carotid body tumour Diseases 0.000 description 1
206010007710 Cartilage injury Diseases 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010008132 Cerebral thrombosis Diseases 0.000 description 1
108091092236 Chimeric RNA Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
208000031879 Chédiak-Higashi syndrome Diseases 0.000 description 1
208000003044 Closed Fractures Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
108010051219 Cre recombinase Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108020001738 DNA Glycosylase Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000028381 DNA glycosylase Human genes 0.000 description 1
101710177611 DNA polymerase II large subunit Proteins 0.000 description 1
101710184669 DNA polymerase II small subunit Proteins 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 description 1
101710132784 Dual specificity protein phosphatase 1 Proteins 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
244000148064 Enicostema verticillatum Species 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
101710198774 Envelope protein US9 Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
208000005917 Exostoses Diseases 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
108010046276 FLP recombinase Proteins 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010001515 Galectin 4 Proteins 0.000 description 1
102100039556 Galectin-4 Human genes 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000034951 Genetic Translocation Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
101000884399 Homo sapiens Arylamine N-acetyltransferase 2 Proteins 0.000 description 1
101000749331 Homo sapiens Claudin-1 Proteins 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
101000739168 Homo sapiens Mammaglobin-B Proteins 0.000 description 1
101001028730 Homo sapiens Transcription factor JunB Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
208000033892 Hyperhomocysteinemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
201000001429 Intracranial Thrombosis Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
206010065433 Ligament rupture Diseases 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
206010024774 Localised infection Diseases 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
208000004852 Lung Injury Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
101000700655 Mycobacterium leprae (strain TN) Serine-rich antigen Proteins 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000009905 Neurofibromatoses Diseases 0.000 description 1
102000008763 Neurofilament Proteins Human genes 0.000 description 1
108010088373 Neurofilament Proteins Proteins 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000032234 No therapeutic response Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
208000002565 Open Fractures Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101150012195 PREB gene Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
208000010886 Peripheral nerve injury Diseases 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 1
102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
208000012641 Pigmentation disease Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000013544 Platelet disease Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
101800001357 Potential peptide Proteins 0.000 description 1
102400000745 Potential peptide Human genes 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
101100022819 Rattus norvegicus Megf6 gene Proteins 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010053879 Sepsis syndrome Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000251131 Sphyrna Species 0.000 description 1
208000029033 Spinal Cord disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
241000223892 Tetrahymena Species 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000003938 Thromboxane Receptors Human genes 0.000 description 1
108090000300 Thromboxane Receptors Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102100037168 Transcription factor JunB Human genes 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
206010069363 Traumatic lung injury Diseases 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
206010054880 Vascular insufficiency Diseases 0.000 description 1
ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
240000006677 Vicia faba Species 0.000 description 1
235000010749 Vicia faba Nutrition 0.000 description 1
235000002098 Vicia faba var. major Nutrition 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
101710086987 X protein Proteins 0.000 description 1
201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000078 anti-malarial effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000007416 antiviral immune response Effects 0.000 description 1
210000002403 aortic endothelial cell Anatomy 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000010420 art technique Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
229920000249 biocompatible polymer Polymers 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
210000001109 blastomere Anatomy 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
210000004903 cardiac system Anatomy 0.000 description 1
208000003295 carpal tunnel syndrome Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000034196 cell chemotaxis Effects 0.000 description 1
230000033026 cell fate determination Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
208000024042 cholesterol ester storage disease Diseases 0.000 description 1
208000013760 cholesteryl ester storage disease Diseases 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000008711 chromosomal rearrangement Effects 0.000 description 1
230000002060 circadian Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
230000019771 cognition Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
235000013367 dietary fats Nutrition 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
201000006828 endometrial hyperplasia Diseases 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000000267 erythroid cell Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
210000003013 erythroid precursor cell Anatomy 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
201000010934 exostosis Diseases 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
235000012041 food component Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000012252 genetic analysis Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000003205 genotyping method Methods 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
210000002288 golgi apparatus Anatomy 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000037308 hair color Effects 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
239000012145 high-salt buffer Substances 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
102000049940 human CLDN1 Human genes 0.000 description 1
102000057767 human SCGB2A1 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
208000021005 inheritance pattern Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000025563 intercellular transport Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000005061 intracellular organelle Anatomy 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
108010028930 invariant chain Proteins 0.000 description 1
230000007794 irritation Effects 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
210000001985 kidney epithelial cell Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
231100000515 lung injury Toxicity 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000003526 lymphopoietic effect Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
229940012189 methyl orange Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000000472 morula Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
229940051866 mouthwash Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
UMWKZHPREXJQGR-XOSAIJSUSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]decanamide Chemical compound CCCCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO UMWKZHPREXJQGR-XOSAIJSUSA-N 0.000 description 1
SBWGZAXBCCNRTM-CTHBEMJXSA-N n-methyl-n-[(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl]octanamide Chemical compound CCCCCCCC(=O)N(C)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SBWGZAXBCCNRTM-CTHBEMJXSA-N 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
210000004296 naive t lymphocyte Anatomy 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
239000006218 nasal suppository Substances 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
201000004931 neurofibromatosis Diseases 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
238000011330 nucleic acid test Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
235000003170 nutritional factors Nutrition 0.000 description 1
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
230000011164 ossification Effects 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
244000045947 parasite Species 0.000 description 1
201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000007030 peptide scission Effects 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
210000002824 peroxisome Anatomy 0.000 description 1
238000002823 phage display Methods 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
210000004214 philadelphia chromosome Anatomy 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
230000027317 positive regulation of immune response Effects 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
229940076376 protein agonist Drugs 0.000 description 1
229940076372 protein antagonist Drugs 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
235000021251 pulses Nutrition 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000025053 regulation of cell proliferation Effects 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000002629 repopulating effect Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006298 saran Polymers 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000003153 stable transfection Methods 0.000 description 1
238000012409 standard PCR amplification Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
231100000617 superantigen Toxicity 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
102000003137 synaptotagmin Human genes 0.000 description 1
108060008004 synaptotagmin Proteins 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
238000003161 three-hybrid assay Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000001875 tumorinhibitory effect Effects 0.000 description 1
238000003160 two-hybrid assay Methods 0.000 description 1
238000010396 two-hybrid screening Methods 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000023577 vascular insufficiency disease Diseases 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Biophysics (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Psychiatry (AREA)

CA002345377A 1998-10-06 1999-10-06 Nouvelles proteines secretees, et polynucleotides les codant Abandoned CA2345377A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US10319598P	1998-10-06	1998-10-06
US60/103,195		1998-10-06
US41223199A	1999-10-05	1999-10-05
US09/412,231		1999-10-05
PCT/US1999/023294 WO2000020447A2 (fr)	1998-10-06	1999-10-06	Nouvelles proteines secretees, et polynucleotides les codant

Publications (1)

Publication Number	Publication Date
CA2345377A1 true CA2345377A1 (fr)	2000-04-13

Family

ID=26800175

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002345377A Abandoned CA2345377A1 (fr)	1998-10-06	1999-10-06	Nouvelles proteines secretees, et polynucleotides les codant

Country Status (6)

Country	Link
EP (1)	EP1119620A2 (fr)
JP (1)	JP2004500011A (fr)
AU (1)	AU766279B2 (fr)
CA (1)	CA2345377A1 (fr)
HK (1)	HK1039783A1 (fr)
WO (1)	WO2000020447A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7014996B1 (en)	1998-10-02	2006-03-21	Diadexus, Inc.	Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
EP1180114B1 (fr) *	1999-04-27	2011-09-21	The Trustees of The University of Pennsylvania	Utilisation d'anticorps spécifiques contre la resistine dans le traitement du diabète
DE60128701T2 (de) *	2000-08-15	2008-02-07	Immunex Corp., Thousand Oaks	Claudin polypeptide
US7186802B2 (en)	2000-08-15	2007-03-06	Immunex Corporation	Claudin polypeptides
WO2002068649A2 (fr) *	2001-01-31	2002-09-06	Curagen Corporation	Proteines et acides nucleiques les codant
US7109302B1 (en)	2002-04-01	2006-09-19	Human Genome Sciences, Inc.	Antibodies that specifically bind to GMAD
DE10254601A1 (de) *	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1431763A1 (fr) *	2002-12-20	2004-06-23	BioVisioN AG	Méthode pour détecter une maladie métabolique
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (fr)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2013167153A1 (fr)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr)	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
CA3169263A1 (fr)	2012-11-13	2014-05-22	Astellas Pharma Inc.	Agents de traitement de maladies cancereuses exprimant claudine
WO2014127785A1 (fr)	2013-02-20	2014-08-28	Ganymed Pharmaceuticals Ag	Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr)	2013-03-18	2014-09-25	Ganymed Pharmaceuticals Ag	Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5707829A (en) *	1995-08-11	1998-01-13	Genetics Institute, Inc.	DNA sequences and secreted proteins encoded thereby
WO1997034997A1 (fr) *	1996-03-21	1997-09-25	Human Genome Sciences, Inc.	Facteur i, ii et iii de liaison de steroides specifique a l'endometre humain
EP0948531A1 (fr) *	1996-12-11	1999-10-13	Chiron Corporation	Proteines humaines secretees
DE19818598A1 (de) *	1998-04-19	1999-10-21	Metagen Gesellschaft Fuer Genomforschung Mbh	Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe

1999
- 1999-10-06 CA CA002345377A patent/CA2345377A1/fr not_active Abandoned
- 1999-10-06 EP EP99951812A patent/EP1119620A2/fr not_active Withdrawn
- 1999-10-06 WO PCT/US1999/023294 patent/WO2000020447A2/fr not_active Application Discontinuation
- 1999-10-06 AU AU64170/99A patent/AU766279B2/en not_active Ceased
- 1999-10-06 JP JP2000574558A patent/JP2004500011A/ja active Pending
2002
- 2002-01-30 HK HK02100720.5A patent/HK1039783A1/zh unknown

Also Published As

Publication number	Publication date
HK1039783A1 (zh)	2002-05-10
WO2000020447A2 (fr)	2000-04-13
AU6417099A (en)	2000-04-26
AU766279B2 (en)	2003-10-16
EP1119620A2 (fr)	2001-08-01
JP2004500011A (ja)	2004-01-08
WO2000020447A3 (fr)	2000-09-28
WO2000020447A8 (fr)	2001-03-08

Publication	Publication Date	Title
AU766279B2 (en)	2003-10-16	Novel secreted proteins and polynucleotides encoding them
WO2001090366A2 (fr)	2001-11-29	Nouveaux polynucleotides humains et polypeptides codes par celui-ci
AU780221B2 (en)	2005-03-10	Polynucleotides and proteins encoded thereby
AU2005200105A1 (en)	2005-02-10	Novel Polynucleotides and Polypeptides Encoded Thereby
EP1171466A2 (fr)	2002-01-16	Recepteur couple a la proteine g et procede d'utilisation dudit recepteur
AU782985B2 (en)	2005-09-15	Novel human proteins and polynucleotides encoding them
US20050250178A1 (en)	2005-11-10	WNT-regulated cytokine-like polypeptide and nucleic acids encoding same
CA2382123A1 (fr)	2001-03-01	Nouveaux polynucleotides exprimes dans les lymphocytes t actives et proteines codees par ces polynucleotides
US20030017457A1 (en)	2003-01-23	Novel polynucleotides and polypeptides encoded thereby
WO2000075321A2 (fr)	2000-12-14	Nouveaux polynucleotides et polypeptides codant pour lesdits polynucleotides
US20020137675A1 (en)	2002-09-26	Polynucleotides and polypeptides encoded thereby
EP1222270A2 (fr)	2002-07-17	Proteines et polynucleotides codes par ces proteines
US20050170380A1 (en)	2005-08-04	Novel human proteins and polynucleotides encoding them
EP1469073A2 (fr)	2004-10-20	Polynucléotides et protéines membranaires codées par ceux-ci
WO2001085783A2 (fr)	2001-11-15	Acides nucleiques codant des polypeptides lies a la sous-unite alpha de la famille des hormones glycoproteiques et procedes d'utilisation de ces derniers
AU1494501A (en)	2001-04-30	Novel polynucleotides and polypeptides encoded thereby
EP1181367A2 (fr)	2002-02-27	Nouveaux polynucleotides et polypeptides codant pour lesdits polynucleotides

Legal Events

Date	Code	Title	Description
2004-10-06	EEER	Examination request
2006-10-06	FZDE	Dead